Kailera Reports Q2 2026 Results: $1.17B Cash, Phase 3 Obesity Trials on Track
KLRA is trading near its 52-week low of $16.39 (13% above the low) on light trading volume (0.4× avg).
Summary
Kailera reported Q2 2026 results with a net loss of $111.3 million and $1.17 billion in cash. The company advanced its obesity pipeline, including an active IND for oral ribupatide and full enrollment in a Phase 2b trial.
Key Events · Earnings and Guidance · KLRA
-
Q2 Net Loss Widens to $111.3M
Net loss for Q2 2026 was $111.3 million, up from $28.9 million in Q2 2025, driven by a $81.5 million increase in R&D expenses to $101.1 million.
-
Cash Runway into Mid-2028
Cash, cash equivalents, and marketable securities totaled $1,171.8 million as of June 30, 2026, expected to fund operations into mid-2028.
-
Oral Ribupatide IND Active
The U.S. FDA has accepted the IND for oral ribupatide, with global Phase 3 obesity trials planned to initiate in the first half of 2027.
-
Phase 2b Injection Trial Fully Enrolled
The U.S. Phase 2b high-dose ribupatide injection trial enrolled 264 participants; data are anticipated in mid-2027.
Analysis · KLRA · Life Sciences
Kailera's second-quarter results show a sharp increase in R&D spending to $101.1 million, reflecting the company's aggressive push into late-stage obesity trials. The $1.17 billion cash position provides runway into mid-2028, but the $111.3 million quarterly net loss underscores the high cost of advancing a diversified GLP-1 pipeline. The active IND for oral ribupatide and full enrollment of the Phase 2b injection trial are concrete steps toward the company's goal of becoming a leader in obesity care.
At the time of this filing, KLRA was trading at $18.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $16.39 to $28.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.